ArticleDrug design, development and therapy2026
Rational Design and Optimization of MCh-AMP1: A Stable α-Helical Antifungal Peptide with Enhanced Activity Against
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Methods: In this study, we engineered MCh-AMP1-A7, a derivative of the natural antimicrobial peptide MCh-AMP1, through rational design to enhance its antifungal activity, stability, and selectivity. By modifying the alpha-helical structure, amphipathy, and cationicity of the peptide, we significantly improved its antimicrobial potency. Results: MCh-AMP1-A7 showed a marked reduction in minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) compared with the parent peptide. Against Discussion: This study provides compelling evidence that MCh-AMP1-A7 is a promising next-generation antifungal agent capable of overcoming the limitations of conventional therapies. The potency, stability, and improved safety profile of the engineered peptide make it a promising candidate for further antifungal development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.